[Update on lipid lowering therapy in peripheral artery disease].

Despite clear guideline recommendations, only about every second PAD patient is prescribed statins, women less often than men. There is an international consensus that every PAD patient should be treated with statins, as these not only lower lipids but also stabilize plaque, resulting in a prognostic benefit. Limb-related endpoints (MALE) can be reduced by 24% compared to placebo by lowering lipids. The combination of low-dose, high-potency statin with ezetimibe can be equivalent to high-dose statin monotherapy and, with better tolerability, promote therapy adherence. Statin intolerance is observed more frequently in certain risk groups but is very rare overall. Effective alternatives are bempedoic acid and PCSK9 inhibitors. About 20% of the population have severely elevated Lp(a) levels that require risk factor management beyond lipid management. A high Lp(a) concentration is associated with PAD progression as an independent risk factor for all atherosclerosis manifestations. Every adult should have an Lp(a) assessment once in their lifetime.
Competing Interests: Die Autorinnen/Autoren geben an, dass kein Interessenkonflikt besteht.
(Thieme. All rights reserved.)